- Previous close
178.78 - Open
179.98 - Bid 192.00 x 800
- Ask 190.49 x 900
- Day's range
179.23 - 183.11 - 52-week range
144.80 - 201.92 - Volume
45,412 - Avg. Volume
1,836,067 - Market cap (intra-day)
82.433B - Beta (5Y monthly) 0.89
- PE ratio (TTM)
35.75 - EPS (TTM)
5.09 - Earnings date 4 Nov 2024
- Forward dividend & yield 1.73 (0.95%)
- Ex-dividend date 31 Oct 2024
- 1y target est
218.58
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
www.zoetis.com14,100
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Recent news: ZTS
View more
Performance overview: ZTS
Trailing total returns as of 01/11/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: ZTS
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: ZTS
View moreValuation measures
Market cap
82.43B
Enterprise value
87.60B
Trailing P/E
35.68
Forward P/E
29.07
PEG ratio (5-yr expected)
2.58
Price/sales (ttm)
9.37
Price/book (mrq)
16.60
Enterprise value/revenue
9.83
Enterprise value/EBITDA
24.12
Financial highlights
Profitability and income statement
Profit margin
26.29%
Return on assets (ttm)
14.41%
Return on equity (ttm)
48.89%
Revenue (ttm)
8.92B
Net income avi to common (ttm)
2.34B
Diluted EPS (ttm)
5.09
Balance sheet and cash flow
Total cash (mrq)
1.57B
Total debt/equity (mrq)
136.57%
Levered free cash flow (ttm)
1.69B